AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $290.07 billion. The enterprise value is $316.56 billion.
| Market Cap | 290.07B |
| Enterprise Value | 316.56B |
Important Dates
The last earnings date was Friday, October 30, 2026, before market open.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 74.04% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 26.20 and the forward PE ratio is 16.84.
| PE Ratio | 26.20 |
| Forward PE | 16.84 |
| PS Ratio | 4.65 |
| Forward PS | 4.39 |
| PB Ratio | 5.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 28.41 |
| P/OCF Ratio | 21.92 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.88, with an EV/FCF ratio of 31.00.
| EV / Earnings | 28.70 |
| EV / Sales | 5.07 |
| EV / EBITDA | 14.88 |
| EV / EBIT | 19.67 |
| EV / FCF | 31.00 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.66.
| Current Ratio | 1.01 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | 3.36 |
| Interest Coverage | 11.05 |
Financial Efficiency
Return on equity (ROE) is 22.57% and return on invested capital (ROIC) is 17.15%.
| Return on Equity (ROE) | 22.57% |
| Return on Assets (ROA) | 8.58% |
| Return on Invested Capital (ROIC) | 17.15% |
| Return on Capital Employed (ROCE) | 18.16% |
| Weighted Average Cost of Capital (WACC) | 5.22% |
| Revenue Per Employee | $655,983 |
| Profits Per Employee | $115,983 |
| Employee Count | 95,100 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.69 |
Taxes
In the past 12 months, AstraZeneca has paid $2.27 billion in taxes.
| Income Tax | 2.27B |
| Effective Tax Rate | 17.04% |
Stock Price Statistics
The stock price has increased by +14.04% in the last 52 weeks. The beta is 0.21, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +14.04% |
| 50-Day Moving Average | 164.48 |
| 200-Day Moving Average | 180.04 |
| Relative Strength Index (RSI) | 75.14 |
| Average Volume (20 Days) | 3,012,121 |
Short Selling Information
The latest short interest is 3.28 million, so 0.21% of the outstanding shares have been sold short.
| Short Interest | 3.28M |
| Short Previous Month | 2.09M |
| Short % of Shares Out | 0.21% |
| Short % of Float | 0.21% |
| Short Ratio (days to cover) | 1.14 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $62.38 billion and earned $11.03 billion in profits. Earnings per share was $7.12.
| Revenue | 62.38B |
| Gross Profit | 51.02B |
| Operating Income | 16.10B |
| Pretax Income | 13.30B |
| Net Income | 11.03B |
| EBITDA | 21.28B |
| EBIT | 16.10B |
| Earnings Per Share (EPS) | $7.12 |
Balance Sheet
The company has $8.17 billion in cash and $34.33 billion in debt, with a net cash position of -$26.16 billion or -$16.87 per share.
| Cash & Cash Equivalents | 8.17B |
| Total Debt | 34.33B |
| Net Cash | -26.16B |
| Net Cash Per Share | -$16.87 |
| Equity (Book Value) | 51.81B |
| Book Value Per Share | 33.35 |
| Working Capital | 181.00M |
Cash Flow
In the last 12 months, operating cash flow was $13.23 billion and capital expenditures -$3.02 billion, giving a free cash flow of $10.21 billion.
| Operating Cash Flow | 13.23B |
| Capital Expenditures | -3.02B |
| Depreciation & Amortization | 5.18B |
| Net Borrowing | 564.00M |
| Free Cash Flow | 10.21B |
| FCF Per Share | $6.58 |
Margins
Gross margin is 81.78%, with operating and profit margins of 25.80% and 17.68%.
| Gross Margin | 81.78% |
| Operating Margin | 25.80% |
| Pretax Margin | 21.32% |
| Profit Margin | 17.68% |
| EBITDA Margin | 34.11% |
| EBIT Margin | 25.80% |
| FCF Margin | 16.37% |
Dividends & Yields
This stock pays an annual dividend of $3.23, which amounts to a dividend yield of 1.73%.
| Dividend Per Share | $3.23 |
| Dividend Yield | 1.73% |
| Dividend Growth (YoY) | 3.19% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 45.34% |
| FCF Payout Ratio | 49.07% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 1.75% |
| Earnings Yield | 3.82% |
| FCF Yield | 3.52% |
Analyst Forecast
The average price target for AstraZeneca is $206.66, which is 10.72% higher than the current price. The consensus rating is "Buy".
| Price Target | $206.66 |
| Price Target Difference | 10.72% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 6.77% |
| EPS Growth Forecast (3Y) | 11.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.6 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.6 |
| Piotroski F-Score | 6 |